Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Sun Pharma announces Japan MHLW approval of ILUMYA™ for the treatment of Plaque Psoriasis

Posted On: 2020-06-29 12:40:02


Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced that one of its wholly-owned subsidiaries has received approval from the Ministry of Health, Labour and Welfare (MHLW), Japan for ILUMYA (tildrakizumab) for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies. Japan has approximately 430,000 people currently suffering from psoriasis.

ILUMYA is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of IL-23 and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of proinflammatory cytokines and chemokines.

Junichi Nakamichi, Country Head, Sun Pharma Japan, said, "ILUMYA is the first innovative drug that Sun Pharma plans to launch in Japan. It was extensively tested in Japanese patients as part of ILUMYA's global clinical development program. The drug offers a new treatment option with only one injection every 12 weeks for Japanese patients who struggle everyday with the chronic nature of plaque psoriasis. It showed sustained efficacy for over 4 years and has safety profiles over 4 years with low rates of severe infections, malignancies and MACEs. This approval adds a biologic product to our existing strong dermatology portfolio in Japan. We will leverage Sun Pharma Japan's robust marketing network to make ILUMYA, a safe and efficacious product, available to dermatologists and patients in Japan."

ILUMYA is one of the key specialty products of Sun Pharma and it was approved by US FDA in March 2018 while the European Commission approved it in September 2018.

The MHLW approval of ILUMYA for the treatment of plaque psoriasis was supported by data from the pivotal Phase-3 reSURFACE clinical development program. In the two multicentre, randomized, doubleblind, placebo-controlled trials (reSURFACE 1 and reSURFACE 2), 1862 adult patients were enrolled and treated with ILUMYA (N=1238), etanercept (N=313) or placebo (N=310). Both Phase-3 studies met the primary efficacy endpoints, demonstrating significant clinical improvement with ILUMYA 100 mg compared to placebo or etanercept when measured by at least 75 percent reduction in baseline psoriasis severity (Psoriasis Area Sensitivity Index or PASI 75) and Physician's Global Assessment (PGA) score of "clear" or "minimal" at week 12 after two doses.

The most common adverse reactions observed with ILUMYA in the pooled data from one Phase 2 and two Phase 3 studies in psoriasis patients for the placebo controlled period (16 weeks for the Phase 2 study and 12 weeks for the Phase 3 studies) were nasopharyngitis, headache, and site injection pain. Most adverse reactions were considered mild and no adverse reaction led to discontinuation of treatment in >1% of patients.

After 64-week base study of reSURFACE 1, a total of 120 Japanese patients entered the reSURFACE 1 extension study and 101 patients completed the extension study for 148 weeks.

Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.479.95 as compared to the previous close of Rs. 487.65. The total number of shares traded during the day was 361548 in over 8374 trades.

The stock hit an intraday high of Rs. 492 and intraday low of 472.5. The net turnover during the day was Rs. 173950241.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

HeidelbergCement India Ltd board to announce quarterly results on July 22, 2020

Asahi Songwon Colors Ltd board to approve Q1FY21 results on July 21, 2020

Mr. Subramanian Sarma Inducted as Executive Director on L&T Board, Mr. S V Desai & Mr. T Madhava Das elevated

Glenmark commences 1000 patients Post Marketing Surveillance study with COVID-19 who are administered FabiFlu®

Quick Heal redefines Consumer Security in India

CARE reaffirms rating of Bhageria Industries Limited

Adani Ports and Special Economic Zone Limited updates on ratings from global rating agencies

Birlasoft intelliOpen™ supports safe return-to-work strategies

Morgan Stanley to Consolidate Mumbai GIC operations to a Single Campus at Oberoi Realty's Commerz III Building in Goregaon

Steel Strips Wheels Ltd receives new orders from EU and USA

MBL Infrastructures Ltd gets three favorable arbitration awards

Gitanjali Gems Ltd to be liquidated

Qualcomm Ventures to invest Rs. 730 crore in Jio Platforms

Aarti Surfactants Limited to list on July 14, 2020

Hindustan Unilever Ltd board to consider quarterly results on July 21, 2020

Avenue Supermarts Ltd reports earnings for Q1FY21

Clariant Chemicals' declares Special Interim Dividend of Rs. 140/- per share

Coastal Corporation Limited announces earnings for Q4FY2020

Fitch Affirms Glenmark Pharmaceuticals at 'BB'; Withdraws Proposed Bond Rating

Deccan Health Care Ltd receives HealthCare Excellence Award 2020

SORIL Infra Resources Ltd Q4 FY2020 consolidated loss at Rs. 1.12 crore

Indiabulls Integrated Services Ltd Q4 consolidated loss at Rs. 51.66 crore

Indian Toners & Developers Ltd Q4 consolidated net profit at Rs. 2.82 crore

Coastal Corporation Ltd Q4FY20 consolidated PAT slides to Rs. 1.62 crore

Shahlon Silk Industries Ltd board recommends dividend of Rs. 0.25

ICRA reaffirms long term ratings of Shalby Limited

Polychem Ltd board recommends dividend of Rs. 12.5 for FY20

Polychem Ltd Q4FY20 consolidated net profit lower at Rs. 0.58 crore

Biocon's Breakthrough Drug Itolizumab Receives DCGI Nod for its Use in Moderate to Severe COVID-19 Patients

Vardhman Polytex Limited in negotiation with banks for OTS

IIFL Securities Ltd board to approve Q1FY2021 results on July 18, 2020

Galaxy Surfactants Limited restarts operations at Tarapur Unit

Chembond Chemicals Ltd posts Rs. 4.03 crore PAT in Q1 FY21

Avenue Supermarts Ltd Q1FY21 consolidated PAT slumps to Rs. 38.98 crore

Clariant Chemicals (India) Limited board approves special interim dividend of Rs. 140

PDS Multinational Fashions Ltd posts Rs. 16.90 crore consolidated PAT in Q4 FY20

Old National Bank and Infosys Forge Digital Transformation Partnership

Dhanuka Agritech Ltd board to announce Q1FY21 results on July 22, 2020

HDFC ERGO Launches Corona Kavach Policy

Karnataka Bank reports earnings for Q1FY21

Gujarat Narmada Valley Fertilizers and Chemicals Ltd Board recommends Dividend of Rs. 5 for FY20

IRB Infra enters Eastern India territory

ITC Ltd board to announce Q1FY21 results on July 24, 2020

Manappuram Finance Ltd raises Rs. 178 crore through NCDs

BASF India Limited approves acquisition of BASF Performance Polyamides

Goa Carbon Ltd resumes operations at Goa plant from July 9, 2020

IRCTC board recommends final dividend of Rs. 2.50 for FY20

Ircon International Limited board recommends final dividend of Rs. 2.06

Rajapalayam Mills Ltd board to consider 1st quarter results on Aug 12, 2020

G N A Axles Ltd board to approve Q1FY21 results on July 17, 2020







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019